title: The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b.
abstract: The fate of the neutralizing antibody (NAB) in MS patients treated with interferons remains unclear. We conducted a follow-up survey of NAB titers in 59 long-term treated patients from the London and Vancouver cohorts of the pivotal trial of interferon alpha-1b. NAB were measured with the myxovirus protein A assay and an ELISA, at a mean follow-up that exceeded 8 years. NAB disappeared in the majority of patients.
authors.affiliation: London MS Clinic, Ontario, Canada.
authors.forename: G P
authors.initials: GP
authors.lastname: Rice
authors.forename: B
authors.initials: B
authors.lastname: Paszner
authors.forename: J
authors.initials: J
authors.lastname: Oger
authors.forename: J
authors.initials: J
authors.lastname: Lesaux
authors.forename: D
authors.initials: D
authors.lastname: Paty
authors.forename: G
authors.initials: G
authors.lastname: Ebers
mesh_terms: D000937:Antigen-Antibody Reactions; D004797:Enzyme-Linked Immunosorbent Assay; D005500:Follow-Up Studies; D006801:Humans; D000068556:Interferon beta-1a; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000627:therapeutic use*; D009103:Multiple Sclerosis / Q000276:immunology* / Q000628:therapy*; D009500:Neutralization Tests; D013997:Time Factors
chemical_list: D000068576:Interferon beta-1b; D016899:Interferon-beta; D000068556:Interferon beta-1a